Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Akela Pharma Inc. AKLPF

"Akela Pharma Inc is engaged in providing contract services comprised of pharmaceutical formulation research and development, pre-clinical, clinical and commercial drug manufacturing, product development and patent litigation support."


GREY:AKLPF - Post by User

Post by modulexon Dec 11, 2012 6:45pm
618 Views
Post# 20715977

AKELA PHARMA INC.

AKELA PHARMA INC.

December 11, 2012
British Columbia Securities Commission
701 West Georgia Street
P.O. Box 10142, Pacific Centre
Vancouver, B.C. V7Y 1L2

To Whom it may Concern:
The Ontario Securities Commission has informed me on December 1, 2012 to contact the British Columbia Securities Commission as it is the Principal Regulator of AKELA PHARMA INC.

Akela Pharma Inc. management has neglected:

1
To duly inform its shareholders via its website WWW.AKELAPHARMA.COM of its headquarters moving from the State of Texas to the State of California in October 2012 and at what address/telephone number(s) the said new headquarters are located in the State of California.

2
To duly inform its shareholders via its website WWW.AKELAPHARMA.COM of its shares delisting from the Toronto Stock Exchange in November 2012 and the outcome of the company shares.

3
To duly inform its shareholders via its website WWW.AKELAPHARMA.COM in November 2012 of what lies ahead for the company, subsequent to its shares delisting?


You will understand that as a company minority shareholder, alike others, I dont appreciate at all the disgraceful behaviour of BREACH OF TRUST undertakenby management of Akela Pharma Inc. in this messy case.


I want to know officially from the British Columbia Securities Commission what recourses are available to bring Akela Pharma Inc.'s management to accountability.

Thank you.




Luc Proulx
LPROEXP@HOTMAIL.COM
Akela Pharma Inc. shareholder
<< Previous
Bullboard Posts
Next >>